AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 5 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel molecular adjuvant can improve the performance of DNA-based HIV vaccines, researchers in North Carolina report.
"DNA vaccines expressing the envelope (Env) protein of the human immunodeficiency virus have been relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies in a variety of animal models," according to Thomas D. Green and colleagues working at East Carolina University in Greenville and Duke University in Durham.
Addition of the complement component C3d augmented the HIV-specific humoral responses induced by an Env-based vaccine in mice, Green and coauthors found.
The researchers evaluated antibody responses to plasmids expressing a fusion protein consisting of Env and as many as three copies of murine C3d (mC3d). Env fused to multiple mC3d copies elicited potent and durable Env-specific antibody activity, they said.
The best results were achieved by priming mice with Env-mC3d DNA and then inoculating them with a purified form of the HIV gp120 coat protein, study data showed. However, Env-MC3d DNA priming increased the rate of antibody avidity maturation after immunization.
Env fused to three copies ...